Philip W. Kantoff, MD, of the Dana-Farber Cancer Institute, emphasized that this was essentially a negative study. “There is no evidence that VEGFR-targeted agents provide a survival benefit for men with advanced prostate cancer,” he indicated. “With shrinking resources and a rapidly improving understanding of the genetic and biologic basis of disease, we need to be more selective about what agents to bring forward to be tested in the phase III setting” said Dr. Kantoff. ■

Financial Disclosure: Dr. Kantoff has been a consultant for Progenics Pharmaceuticals, Inc, Amgen USA, Tokai, BN ImmunoTherapeutics, Ortho Biotech, Bellicum, Genentech, and Johnson & Johnson. He has served on the science advisory board for BIND Biosciences, Inc, and the data safety monitoring boards for Celgene, Millennium, and OncoGeneX.